Recently, the Head of Global Business Development at Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", 688136.SH) was invited to attend the 2026 BFC-Cytiva Global Healthcare Summer BD & Investment Conference.

Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly owned subsidiary of Kexing Biopharm, successfully completed the first participant enrollment and dosing in the Phase I clinical study of GB19 Injection

Reminton® (Infliximab for Injection), introduced by Kexing Biopharm from Mabpharm, has recently received approval from the National Medical Products Administration (NMPA) for a new indication.

From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center.

Recently, Kexing Biopharm (688136.SH) and Sinotherapeutics (688247.SH) signed an exclusive commercialization licensing agreement for Tofacitinib Citrate Sustained-Release Tablets in the Kuwait and Mexico markets, jointly advancing the product’s expansion into international markets.

Kexing Biopharm's oncology product for international markets, Paclitaxel for Injection (Albumin-Bound) (Apexelsin®), has recently received marketing approval from the Institute of Public Health of Chile (ISP Chile).

Recently, the Key Trademark Protection Committee of the Guangdong Trademark Association officially released the 2025 Guangdong Key Trademark Protection List.

May 19 marks World IBD Day, a global initiative dedicated to raising public awareness of Inflammatory Bowel Disease (IBD) and promoting better disease management and quality of life for patients.